Nanosuspensions as a versatile carrier based drug delivery system – an overview

Current Drug Delivery

Volumn 11, Issue 3, 2014, Pages 299-305

  Sudhakar, Beeravelli ^a   NagaJyothi, Kothagunda ^a   Ramana Murthy, K V ^a  

^a ANDHRA UNIVERSITY   (India)

Author keywords

Bioavailability enhancement; Carrier systems; Dissolution; Nanosizing; Nanosuspensions; Parenteral

Indexed keywords

2 METHOXYESTRADIOL; ACICLOVIR; APREPITANT; CANDESARTAN HEXETIL; DOCETAXEL; FELODIPINE; FENOFIBRATE; FLURBIPROFEN; ITRACONAZOLE; MEGESTROL ACETATE; NANOMATERIAL; NEVIRAPINE; RAPAMYCIN; RIBOFLAVIN; RILPIVIRINE; SOLVENT; TELMISARTAN; NANOPARTICLE; SUSPENSION;

ANTIHYPERTENSIVE THERAPY; ARTICLE; BOUNDARY LAYER; CRYSTALLIZATION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG SOLUBILITY; DRUG STABILITY; FLUIDIZATION; HUMAN; HYDRODYNAMICS; NANOTECHNOLOGY; PARTICLE SIZE; PRECIPITATION; PRIORITY JOURNAL; SEDIMENTATION; SUPERCRITICAL FLUID; ADMINISTRATION AND DOSAGE; SUSPENSION;

DRUG DELIVERY SYSTEMS; DRUG STABILITY; HUMANS; NANOPARTICLES; SUSPENSIONS;

EID: 84912010261     PISSN: 15672018     EISSN: 18755704     Source Type: Journal    
DOI: 10.2174/1567201811666140323131342     Document Type: Article

References (29)

1. Muller, RH.; Jacobs, C.; Kayser, O. Nanosuspensions as particulate drug formulations in therapy Rationale for development and what we can expect for the Future. Adv. Drug Deliv. Rev., 2001, 47, 3-19.
2. Kocbek, P.; Baumgartner, S.; Kristl, J. Preparation and evaluation of nanosuspensions for enhancing the dissolution of poorly soluble drugs. Int. J. Pharm., 2006, 312, 179-186.
3. Kesisoglou, F.; Amitava, M. Crystalline Nanosuspensions as Potential Toxicology and Clinical Oral Formulations for BCS II/IV Compounds. AAPS J., 2012, 14, 677-687.
4. Pignatello, R.; Bucolo, C.; Spedalieri, G.; Maltese, A.; Puglisi, G. Flurbiprofen-Loaded Acrylate Polymer Nanosuspensions For Ophthalmic Application. Biomater. Sci.,2002, 23, 3247-3255.
5. Pignatelloa, R; Claudio, B; Piera, F; Adriana, M; Antonina, P; Giovanni, P. E udragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen. Eur. J. Pharm.,2002, 16, 53-61.
6. Lili, W.; Zhihong, L.; Donghua, L.; Chunxi, L.; Zhang, J.; Na, Zhang. Docetaxel-loaded-lipid-based nanosuspensions (DTXLNS): Preparation, pharmacokinetics, tissue distribution and antitumor activity. Int. J. Pharm., 2011, 413, 194-201.
7. Lina, D.; Guanglong, L.; Yiguang, J.; Lin, W.; Qishou, X.; Junxing, D. Riboflavin Laurate Nanosuspensions As An Intramuscular Injection For Long-Term Riboflavin Supplementation. Int. J. Pharm.,2013, 450, 338-344.
8. Horter, D.; Dressman, J.B. Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. Adv. Drug Deliv. Rev., 2001, 46, 75-87.
9. Mosharraf, M.; Nystrom, C. The effect of particle size and shape on the surface specific dissolution rate of micronized practically insoluble drugs. Int. J. Pharm., 1995, 122, 35-47.
10. Muller, R.H.; Peters, K. Nanosuspensions for the formulation of poorly soluble drugs prepared by a size-reduction technique. Int. J. Pharm., 1998, 160, 229-37.
11. Peng, L.; Xinyu, R.; Johanna, L.; Bert van, V.; Juha, K.; Jouni, H.; Timo, L.; Leena, P. Nanosuspensions of poorly soluble drugs: Preparation and development of Wetmilling. Int. J. Pharm., 2011, 411, 215-222.
12. Michael, J.; Martin, D.; John, E. Generation of wear during the production of drug nanosuspensions by wet media milling. Eur. J. Pharm. Biopharm., 2012, 81, 214-222.
13. Hak-Kim, C.; Philip ChiLip, K. Production methods for nanodrug particles using the bottom-up approach. Adv. Drug Deliv. Rev., 2011, 63, 406-416.
14. BernardVan, E.; Bernard, S.; Ludo, F.; Jan Van, H.; Johan A.M.; Patrick, A.; GuyVanden, M. Downscaling Drug Nanosuspension Production: Processing Aspects and Physicochemical Characterization. AAPS Pharm. Sci. Tech., 2009, 10,43-53.
15. Nae-Oh Chung.; Min Kyung Lee; Jonghwi Lee. Mechanism of freeze-drying drug nanosuspensions. Int. J. Pharm.,2012, 437, 42-50.
16. Libo Wu.; Jian Zhang; Wiwik Watanabe. Physical and chemical stability of drug nanoparticles. Adv. Drug Deliv. Rev., 2011, 63, 456-469.
17. Engstrom, J.D.; Tam, J.M.; Miller, M.A.; Williams, R.O.; Johnston, K.P. Templated open flocs of nanorods for enhanced pulmonary delivery with pressurized metered dose inhalers. Pharm. Res., 2009, 26, 101-117.
18. Sudhir V.; Sumit K.; Rajeev G.; Diane B., J. Physical stability of nanosuspensions: Investigation of the role of stabilizers on Ostwald ripening. Int. J. Pharm., 2011, 406, 145-152.
19. Kumar, B.S.; Sabera, K.; Irin P.L. Increasing Possibilities of Nanosuspension. J. Nanotechnol., 2013, 2013, 1-13.
20. Patravale, V.B.; Abhijit, A.D.; Kulkarni, R.M. Nanosuspensions: a promising drug delivery strategy. JPP., 2004, 56, 827-840.
21. Panayiotis, P.; Constantinides; Mahesh, V.C.; Robert, S. Advances in lipid nano dispersions for parenteral drug delivery and targeting. Adv. Drug Deliv. Rev., 2008, 60, 757-767.
22. Chetan, D.; Sandip, C.; Krutika, S. Enhanced Antihypertensive Activity of Candesartan Cilexetil Nanosuspension: Formulation, Characterization And Pharmacodynamic Study. SCI Pharm., 2011, 79, 635-651.
23. BhanuSahu, P.; MalayDas, K. Nanosuspension for enhancement of oral bioavailability of felodipine. Appl. Nanosci., 2012, 3, 1-9.
24. Thakur, D.; Bharadia, P.; Pandya, V. Enhancement of poorly water soluble antihypertensive drug by nanosizing approach. J. Pharm. Bioall. Sci., 2012, 4, 40-41.
25. GerbenVant, K.; Eva, H.; Herman, B.; Adriana, L.; Marie-Paule, B.; FransVan, V.; Lieven, B. Pharmacokinetics and Disposition of Rilpivirine (TMC278) Nanosuspension as a Long-Acting Injectable Antiretroviral Formulation. Antimicrob. Agents Chemother., 2010, 54, 2042-2050.
26. Panchaxari, D.; Shashidhar, K.; Vinayak, M.; Anand, G.; Anandrao, K. Polymeric ocular nanosuspension for controlled release of acyclovir: in vitro release and ocular distribution. Iran J. Pharm. Res., 2009, 8, 79-86.
27. Ranjita, S.; Kamalinder Singh, K. Nevirapine nanosuspensions: stability, plasma compatibility and sterilization. Int. J. Pharm. Investig., 2012, 42, 257-269.
28. Xiaohui, P.; Jin, S.; Yan, W.; Yongjun, W.; Xiaohong, L.; Peng, Z.; Xing, T; Weisan, P.; Jihong, H.; Zhonggui, H. Development of a chemically stable 10-hydroxycamptothecin nanosuspensions. Int. J. Pharm., 2009, 379, 167-173.
29. Nakarani, M.; Misra, A.K.; Patel, J.K.; Vaghani, S.S. Itraconazole nanosuspension for oral delivery: formulation, characterization and in vitro comparison with marketed formulation. Daru., 2010, 18, 84-90.